Prisca HavranekKosicek - Novozymes President
| NVZMY Stock | USD 55.03 0.57 1.05% |
President
Ms. Prisca HavranekKosicek was appointed Chief Financial Officer and Executive Vice President, Corporationrationrate Functions at NOVOZYMES AS, effective as of February 1, 2018. Until November 2017, she was Member of the Management and Chief Financial Officer at Kuoni group. Before that, she held various positions at Royal DSM from 2011 till 2016, including as Group Treasurer and CFO for DSM pharma division. Between 2004 and 2008, she was Vice President, Corporationrationrate Subsidiaries and Investor Relations at Austrian Airlines Group. She holds Ph.D. in Business Administration from University of Economics and Business in Vienna. She is Member of the Board of Allianz Elementar VersicherungsAG and Allianz Elementar LebensversicherungsAG. since 2018.
| Age | 42 |
| Tenure | 6 years |
| Phone | 45 44 46 00 00 |
| Web | https://www.novozymes.com |
Novozymes Management Efficiency
The company has return on total asset (ROA) of 0.1062 % which means that it generated a profit of $0.1062 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2789 %, meaning that it generated $0.2789 on every $100 dollars invested by stockholders. Novozymes' management efficiency ratios could be used to measure how well Novozymes manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 6 records | PRESIDENT Age | ||
| Chris Bitsakakis | AirBoss of America | N/A | |
| Lisa Swartzman | AirBoss of America | 43 | |
| Yvan Ambeault | AirBoss of America | N/A | |
| Douglas Reid | AirBoss of America | N/A | |
| Earl Laurie | AirBoss of America | N/A | |
| Robert Dodd | AirBoss of America | N/A | |
Management Performance
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 |
Novozymes AS Leadership Team
Elected by the shareholders, the Novozymes' board of directors comprises two types of representatives: Novozymes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novozymes. The board's role is to monitor Novozymes' management team and ensure that shareholders' interests are well served. Novozymes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novozymes' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Videbaek, COO and Executive VP of Bus. Devel. | ||
| Tobias Bjorklund, Head of Investor Relations | ||
| Ester Baiget, Pres CEO | ||
| Kasim Kutay, Director | ||
| Anders Lund, Executive Vice President Household Care & Technical Industries | ||
| Agnete RaaschouNielsen, Director | ||
| Thomas Nagy, Executive VP of Supply Operations | ||
| Pedro Fernandes, Head America | ||
| Joergen Rasmussen, Independent Director | ||
| Andrew Fordyce, Executive VP of Food and Beverages | ||
| Lena Halskov, Director, Employee Representative | ||
| Tue Micheelsen, VP Marketing | ||
| Sebastian Sderberg, VP Acquisitions | ||
| Martin Riise, Head of Investor Relations | ||
| Peder Nielsen, CEO and Pres | ||
| Prisca HavranekKosicek, CFO & Executive Vice President Corporate Functions | ||
| HeinzJuergen Bertram, Independent Director | ||
| Benny Loft, CFO and Executive VP | ||
| Anders Knudsen, Director, Employee Representative | ||
| Lena Olving, Independent Director | ||
| Mathias Uhlen, Independent Director | ||
| Graziela Malucelli, Supply Operations | ||
| Patricia Malarkey, Director | ||
| Henrik Gurtler, Chairman of the Board | ||
| Per Falholt, Consultant | ||
| Kim Stratton, Director | ||
| Tina Fanoe, Executive Vice President Agriculture & Bioenergy | ||
| Morten Rasmussen, Sustainability People | ||
| Thomas Bomhoff, Head of Investor Relations | ||
| Lars Green, Director | ||
| MSc MSc, Ex CFO | ||
| Lars Koeppler, Independent Director, Employee Representative |
Novozymes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novozymes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 14.47 B | |||
| Shares Outstanding | 276.6 M | |||
| Price To Earning | 34.25 X | |||
| Price To Book | 6.12 X | |||
| Price To Sales | 0.80 X | |||
| Revenue | 17.55 B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novozymes in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novozymes' short interest history, or implied volatility extrapolated from Novozymes options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novozymes AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Novozymes Pink Sheet analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |